Further, treatment with an anti-CD47 blockingantibody synergized with rituximab treatment to promote phagocytosis in vitro and toeliminate cancer cells in an in vivo xenograft model of non-Hodgkin lymphoma (Chao et al., 2010b). This evidence concerns the gene CD47 and non-Hodgkin lymphoma.